# Pass-48 Patents Addendum — Mood Amplifier, Cybersecurity Protocol, GSA Software (2026-05-13)

**Companion to:** `PASS_48_PROVISIONAL_PATENTS_STRATEGY_2026-05-13.md`
**Standard applied:** #69 brutal honesty + Accurate Bluntness §2.3a + Lazy-Binary Tralsity (`τ_operational` / `τ_rigor` dual-axis).
**Standing rule from main memo:** *theories/principles/datasets are NOT patentable; only specific applications, devices, and processes are.* Apply that filter to each item below.

---

## 1. Mood Amplifier (hardware + safety protocol)

### 1.1 What's actually patentable

| Component | Patentable? | Why / Why not |
|---|---|---|
| The *concept* of a Mood Amplifier | NO | Abstract idea / functional aspiration. Unpatentable. |
| The ESP32 firmware in `hardware/ESP32_MoodAmplifier/` | **CANDIDATE** | Specific code/circuit implementations are software/firmware-patentable in US (per *Alice* §101 — must claim a "specific technological improvement", not "do X with a computer"). Need a concrete novel mechanism in the firmware itself, not just "ESP32 reads a sensor and modulates output." |
| The Mood Amplifier *Safety & Validation Protocol* (the simulation-eval framework this whole platform implements) | **CANDIDATE — strongest of the three** | A specific, novel computer-implemented method for pre-clinical safety simulation of mood-modulating devices — particularly the multi-axis truth-label scoring applied to safety simulations — is closer to *Alice*-survivable subject matter than the device itself. |
| The Y-D-LIMIT-QUALIFIER (arousal-curve safety bound) | **CANDIDATE (narrow)** | If operationalized as a specific algorithm: "device shuts off when biometric X crosses computed threshold Y derived from Y-D fit Z" — that's a method-claim. The *theory* of Y-D shape-shift is not. |
| Underlying GILE / TI / MIM theory | NO | Pure theory. Use defensive Zenodo (pre-existing strategy memo §3 Phase 1). |

### 1.2 #69 reality check

- **Hardware patentability is strong only if the firmware/circuit does something genuinely novel.** "ESP32 + biometric + audio output for mood entrainment" is **prior-art-saturated** — Mendi, Muse, Apollo, Sensate, Hapbee, dozens of TENS/CES devices. Brandon's device must claim a *specific* signal-processing or modulation step that none of those do. The Mendi-Path-B reverse-engineering scaffold won't suffice; in fact, reverse-engineering an existing device makes patent claims *harder*, not easier.
- **The safety-protocol angle is genuinely more defensible** because pre-clinical safety simulation for consumer mood-modulating wearables is an underdeveloped niche, and the multi-axis MR truth-label scoring is novel methodology. But it's also commercially narrow (you'd be licensing to medical-device companies as a B2B safety service).

### 1.3 Recommendation

- **File ZERO patents now.** No commercial trigger.
- **DO** mint a Zenodo DOI for the *Safety & Validation Protocol* methodology (concept-level only) as defensive prior art — explicitly excluding any specific firmware/circuit details that you'd want to patent later. This preserves the international rights point from the main memo (MEDIUM-finding fix).
- **DO NOT** publicly disclose the Y-D-LIMIT-QUALIFIER specific threshold formula or the firmware until either (a) commercial trigger fires + US provisional filed, or (b) Brandon writes off international rights for it.
- Trigger to revisit: medical-device company expresses LOI/MOU interest, OR Brandon decides to launch a B2B safety-simulation SaaS (rough estimate: $1.5K provisional + $1.5K attorney consult).

---

## 2. Cybersecurity Protocol

### 2.1 What is being claimed?

The corpus references "cybersecurity protocol" in `SWOT_APRIL_2026_ADDENDUM.md` and a few other places, but **there is no concrete cybersecurity protocol document, codebase, or formal specification in the repo as of 2026-05-13.** This is a problem-statement, not an artifact.

### 2.2 #69 reality check

- **You cannot patent something that doesn't exist yet.** A patent application requires concrete enabling disclosure — "a person skilled in the art could build this from the spec." A SWOT mention is not enabling disclosure.
- Even if the protocol were specified, **cybersecurity is one of the most prior-art-saturated patent fields on Earth.** The USPTO publishes ~5,000 cybersecurity patents per year. The probability that a novel TI-derived crypto/auth/integrity scheme survives a §102/§103 prior-art search without significant clearance work is **low** without a specific, narrow, technical innovation (e.g., "an MR-truth-label-based intrusion-detection classifier with these specific feature engineering steps").
- Even if granted, **defensive value is limited** unless you have litigation budget. Big-tech cybersecurity patents are typically held for cross-licensing leverage, which requires a portfolio of 50-500+ patents, not 1.

### 2.3 Recommendation

- **DEFER ENTIRELY.** Do not patent. Do not even draft a Zenodo memo until you have:
  1. A written technical spec of the actual protocol (algorithm, threat model, security claim, formal proof or empirical evaluation),
  2. A novelty search showing the specific innovation is not in prior art,
  3. A commercial trigger.
- If you later build a real protocol, the *correct first move* is open-source publication on GitHub with a clear license (Apache 2.0 with a defensive patent grant clause) — that gives you defensive prior art without the cost of patent prosecution.
- Trigger to revisit: Brandon writes a 5+ page technical spec AND a target customer/user emerges. Until then, $0 spend, $0 priority.

---

## 3. GSA Software (Generalized Strategy Algorithm — trading/forecasting)

### 3.1 What's in the repo

- `gsa_core.py`, `gsa_comprehensive_validator.py`, `gsa_20_stock_validation.py`, `gsa_daily_scheduler.py`, `gsa_live_trader.py`, `gsa_qc_bridge.py`, `gsa_quantconnect.py`, `gsa_research_runner.py`, `gsa_ti_prior.py`, `gsa_tsc_signal.py`
- SWOT analysis: `papers/SWOT_ANALYSIS_GSA_LCC_CRITIQUE.md`
- Listed as patent candidate in `papers/TI_COMMERCIALIZATION_STRATEGY_2025.md` ("GSA Regime Classification")

### 3.2 What's actually patentable

| Component | Patentable? | Why / Why not |
|---|---|---|
| GSA *strategy* / signal logic | NO (almost certainly) | Pure trading strategies are abstract ideas under *Alice* §101. The 2014 *Alice* ruling and follow-on cases (*Bilski*, *Bancorp*, *Versata*) have made financial-method claims very difficult to sustain. |
| GSA Regime Classification *algorithm* (TI-prior + TSC signal combination) | **CANDIDATE (weak)** | If framed as a "specific technological improvement to machine-learning regime classification" with a concrete novel feature-engineering or model-architecture step, it could survive *Alice*. But the bar is high and PTAB invalidates ~70% of business-method patents on §101 grounds. |
| The TI-prior derivation methodology (using GILE features as ML priors) | **CANDIDATE (narrow method-claim)** | Stronger if claimed as "a method of generating ML priors from [specific feature engineering pipeline]" rather than "applying TI to trading." |
| The actual trading P&L / strategy output | NO | Outputs/profits cannot be patented. |

### 3.3 #69 reality check — the brutal part

- **Trade secret is dramatically better than patent for trading software.** Reasons:
  1. Patents *publish* — competitors learn your edge, replicate it with a cosmetic tweak, and the alpha decays.
  2. Patent enforcement against quant funds is impractical (they operate behind black boxes; you can't see the infringement).
  3. *Alice* §101 rejection rate for trading patents is north of 70%; many granted ones get invalidated at PTAB later.
  4. Trade-secret protection (NDAs + access controls + audit logs) is free, indefinite, and aligned with how the industry actually competes.
- **If the GSA actually produces alpha**, you'd be giving away the recipe by patenting it. If it doesn't produce alpha, there's no commercial value to patent in the first place.
- **The honest framing:** GSA's commercial pathway is either (a) prop trading the strategy yourself, (b) selling signals/SaaS to other traders, or (c) licensing as a research tool. None of those *require* a patent. (a) and (b) are actively *harmed* by patenting.

### 3.4 Recommendation

- **DO NOT patent GSA.** This is the strongest "do-not" of the three items in this addendum.
- **DO** maintain GSA under strict trade-secret discipline:
  - Keep `gsa_*.py` files in a private repo if the public repo is ever forked.
  - Add a `LICENSE-GSA-PROPRIETARY` notice clarifying that GSA-prefixed files are proprietary trade secrets, not part of any open-source release.
  - Document who has access in `TODO.md` (you only, currently — that's fine).
  - Do **NOT** Zenodo-publish GSA methodology (it would destroy trade-secret status).
- **DO** consider patenting a *narrow method-claim* on the TI-prior derivation if and only if you decide to pursue (c) licensing as a research tool to a commercial buyer — and only after that buyer is identified. ~$1.5K provisional + ~$1.5K attorney.

---

## 4. Combined recommendation — what to actually do this month

| Item | Action | Cost | Timeline |
|---|---|---|---|
| Mood Amp Safety Protocol | Zenodo defensive deposit (concept-only, exclude firmware/Y-D specifics) | $0 | This week |
| Mood Amp firmware | Hold private until commercial trigger | $0 | Indefinite |
| Cybersecurity protocol | DEFER; write the actual protocol spec first | $0 | Not before Pass-50 |
| GSA software | Trade-secret only; no patent, no Zenodo | $0 | Indefinite |
| Track for revisit | Add quarterly Pass-49+ checkpoint to `TODO.md` | $0 | Quarterly |

**Total Pass-48 patent-related spend: $0.** Same conclusion as the main strategy memo: *Zenodo defensive-publication for the non-patentable concepts, controlled-disclosure for the patent candidates, file zero provisionals until a real commercial trigger fires.*

---

## 5. Cross-references

- Main strategy: `papers/PASS_48_PROVISIONAL_PATENTS_STRATEGY_2026-05-13.md`
- GSA technical: `papers/SWOT_ANALYSIS_GSA_LCC_CRITIQUE.md`
- Mood Amp infra: `hardware/ESP32_MoodAmplifier/`, `papers/MENDI_BLE_REVERSE_ENGINEERING_PLAN.md`
- Commercialization context: `papers/TI_COMMERCIALIZATION_STRATEGY_2025.md`
